SINEQUAN
What it isTricyclic with very high H1 affinity; at low dose an insomnia agent, at high dose an antidepressant.
Why this oneAt 3 to 6 mg it is essentially a pure H1 antagonist, giving sleep maintenance without anticholinergic or dependence effects.
What limits itAt antidepressant doses it becomes a full tricyclic with all the anticholinergic and overdose liability. The dose determines which drug it is.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Insomnia (sleep maintenance) | Adults | 6 mg QHS | 6 mg QHS | 6 mg/day |
| Insomnia (sleep maintenance) | Elderly ≥65 y | 3 mg QHS | 3–6 mg QHS | 6 mg/day |
Renal Undefined
Hepatic Initiate at 3 mg; monitor closely for daytime effects
Pregnancy No established increased risk of major birth defects/miscarriage; risk of poor neonatal adaptation with third-trimester TCA exposure
Lactation Doxepin/nordoxepin present in milk; reports of sedation, respiratory depression, poor feeding, hypotonia — breastfeeding not recommended
⚠ BOXED WARNING
Cost, est. cash$5–$150/month
Generic entry1986
Legacy pregnancy categoryC
Defining liabilityTricyclic anticholinergic and cardiac toxicity become life-threatening in overdose.

Open Doxepin in the interactive console ↗
